MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Tyme Technologies ROA Ratio 2011-2026 | TYME
Annual ROA Ratio Tyme Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -26.28 | -74.58 | -188.3 | -61.16 | -141.87 | - | -261.18 | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -26.28 | -261.18 | -125.56 |
Quarterly ROA Ratio Tyme Technologies
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -21.92 | -19.54 | -36.73 | -28.66 | -34.03 | -67.03 | -77.54 | -100.36 | -124.9 | -136.85 | -148.71 | -147.84 | -136.15 | -127.37 | -121.31 | -121.59 | -120.5 | -122.73 | -149.24 | -145.63 | -155.3 | -209.11 | -242.23 | -288.98 | -356.95 | -304.87 | -313.62 | -303.96 | -248.18 | -752.24 | -1200.28 | -1230.54 | -716.11 | -20374.94 | -39483.84 | -74670.06 | -55020.38 | -55102.36 | -35525.51 | -315.17 | -321.32 | -344.92 | -286.54 | -242.53 | -70.79 | -23.6 | -23.6 | -23.6 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -19.54 | -74670.06 | -6044.59 |
ROA Ratio of other stocks in the Biotechnology industry
| Issuer | ROA Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-20.13 | - | 2.43 % | $ 254 M |  Germany |
 |
Graybug Vision
GRAY
|
-217.51 | - | -11.23 % | $ 9.65 M |  USA |
 |
Apellis Pharmaceuticals
APLS
|
2.08 | $ 20.16 | -2.61 % | $ 2.54 B | USA |
 |
Aptorum Group Limited
APM
|
-26.46 | $ 0.79 | -6.17 % | $ 4.31 M |  China |
 |
I-Mab
IMAB
|
7.43 | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
3.33 | - | - | $ 40.3 B | USA |
 |
Acer Therapeutics
ACER
|
-225.71 | - | 2.71 % | $ 14 M | USA |
 |
Biophytis SA
BPTS
|
-89.6 | - | -13.47 % | $ 169 M |  France |
 |
Ampio Pharmaceuticals
AMPE
|
-150.49 | - | -11.43 % | $ 502 K | USA |
 |
AbCellera Biologics
ABCL
|
-10.79 | $ 3.71 | -2.88 % | $ 1.11 B |  Canada |
 |
Athersys
ATHX
|
-144.48 | - | 3.77 % | $ 22.4 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-53.39 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-42.28 | - | -18.52 % | $ 27.3 M |  Britain |
 |
AVEO Pharmaceuticals
AVEO
|
-50.64 | - | - | $ 521 M | USA |
 |
Axsome Therapeutics
AXSM
|
-26.55 | $ 164.05 | -1.4 % | $ 8.16 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-634.44 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
26.14 | - | -4.8 % | $ 255 M | USA |
 |
Burford Capital Limited
BUR
|
5.51 | $ 8.55 | -2.06 % | $ 1.39 B | Britain |
 |
BridgeBio Pharma
BBIO
|
-78.3 | $ 64.53 | -1.48 % | $ 12.4 B | USA |
 |
Adverum Biotechnologies
ADVM
|
-72.8 | - | - | $ 86.2 M | USA |
 |
CymaBay Therapeutics
CBAY
|
-24.24 | - | - | $ 3.45 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
4.82 | - | - | - |  Russia |
 |
Avid Bioservices
CDMO
|
-41.82 | - | - | $ 789 M | USA |
 |
ARCA biopharma
ABIO
|
-21.14 | - | 1052.0 % | $ 415 M | USA |
 |
BioMarin Pharmaceutical
BMRN
|
4.59 | $ 58.53 | -2.03 % | $ 11.2 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
-752.78 | - | - | $ 169 M | USA |
 |
Caladrius Biosciences
CLBS
|
-57.1 | - | -16.75 % | $ 25.8 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-20.15 | - | - | $ 2.17 B | USA |
 |
Clovis Oncology
CLVS
|
-55.94 | - | -7.23 % | $ 13 M | USA |
 |
Acorda Therapeutics
ACOR
|
-232.99 | - | -24.86 % | $ 820 K | USA |
 |
Checkmate Pharmaceuticals
CMPI
|
-77.89 | - | - | $ 231 M | USA |
 |
Acasti Pharma
ACST
|
-13.29 | - | 4.01 % | $ 150 M | Canada |
 |
CTI BioPharma Corp.
CTIC
|
-73.85 | - | - | $ 1.2 B | USA |
 |
CohBar
CWBR
|
-74.39 | - | -15.44 % | $ 2.2 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-273.86 | - | -5.98 % | $ 34.1 M | USA |
 |
Cyclacel Pharmaceuticals
CYCCP
|
-273.86 | - | -4.36 % | $ 27 M | USA |
 |
Cabaletta Bio
CABA
|
-26.68 | $ 3.25 | -1.52 % | $ 3.8 M | USA |
 |
Deciphera Pharmaceuticals
DCPH
|
-41.16 | - | - | $ 2.18 B | USA |
 |
CureVac N.V.
CVAC
|
-35.55 | - | - | $ 867 M | Germany |
 |
Capricor Therapeutics
CAPR
|
-37.95 | $ 25.84 | -3.8 % | $ 692 M | USA |
 |
Aeterna Zentaris
AEZS
|
-10.45 | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-123.72 | - | -10.17 % | $ 12.2 K | USA |
 |
Codexis
CDXS
|
-43.81 | $ 0.98 | -3.92 % | $ 71.9 M | USA |
 |
Certara
CERT
|
-0.1 | $ 7.24 | 2.7 % | $ 1.16 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-19.95 | - | - | $ 1.01 B | USA |
 |
Entasis Therapeutics Holdings
ETTX
|
-115.2 | - | - | $ 105 M | USA |
 |
Evofem Biosciences
EVFM
|
501.98 | - | 7.55 % | $ 38.1 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-27.57 | - | - | $ 26.5 M | USA |
 |
Coherus BioSciences
CHRS
|
-37.78 | $ 1.65 | - | $ 155 M | USA |
 |
Evelo Biosciences
EVLO
|
-177.72 | - | -14.46 % | $ 27.9 M | USA |